ECOG 1594 — Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer

Phase 3 · 2002 · Non-Small Cell Lung Cancer

Design

Randomized phase III trial comparing four platinum-based doublets (cisplatin/paclitaxel [reference], cisplatin/gemcitabine, cisplatin/docetaxel, and carboplatin/paclitaxel) as first-line therapy.

Population

1,207 patients with advanced (stage IIIB/IV) non-small-cell lung cancer who had not received prior chemotherapy.

Primary Endpoint

Overall survival

Key Result

No regimen was superior to another, with an overall median survival of 7.9 months, 1-year survival of 33%, and response rate of 19%, establishing therapeutic equivalence among the doublets.

Guideline Impact

Defined platinum-doublet chemotherapy as the first-line standard of care in advanced NSCLC guidelines.